MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the Infusion Nurses Society Annual Meeting and Exhibition, to be held in Kansas City, Missouri from Saturday, May 18 to Monday, May 20, 2024. Visitors to Covalon’s booth (#420) will have the opportunity to explore the Company’s innovative vascular access and infection control solutions first-hand and learn why many top hospitals are choosing Covalon solutions for their patients.
“One of our primary goals is to give patients a feeling of freedom during infusion treatments – freedom from the worry of painful dressing removals and skin injuries,” said Brent Ashton, Chief Executive Officer, Covalon. “Our dressings are unique due to their exceptional coverage, composition, and chemistry. Our state-of-the-art silicone-based vascular access dressings merge safety and efficacy with empathy, moving us closer to providing patient care that is as compassionate as it is effective.”
Not all vascular access dressings are made the same, and Covalon is excited to showcase more compassionate solutions at the Infusion Nurses Society Annual Meeting and Exhibition. The event brings together hundreds of infusion therapy professionals from all over the globe to learn about the latest improvements to patient care and see the newest products on the infusion market. It offers a unique opportunity for healthcare providers to engage with leading-technologies and enhance their practice with the latest innovations.
Covalon’s patented vascular access products include:
- VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
- IV Clear® - the world’s only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment and utilizes gentle silicone adhesive technology to help protect skin from injuries.
- CovaClear® IV – utilizes soft silicone adhesive technology to help protect patients from skin injuries, but does not incorporate antimicrobials, for use with patients who either do not require or cannot tolerate antimicrobials.
To book an appointment with a Covalon representative, please email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at rhebert@covalon.com.
Meeting & Exhibit Details
Meeting Dates: May 18 – 21, 2024
Exhibit Dates: May 18 – 20, 2024
Location: Sheraton Kansas City Hotel at Crown Center (2345 McGee Street, Kansas City, MO 64108 United States)
Register at: https://www.ins1.org/educational-programming/annual-meeting
For healthcare providers who are not able to attend the conference but are interested in learning more about Covalon’s solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, or Instagram.
About Covalon
Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
©2024 Covalon Technologies Ltd.
